Blood functional assay for rapid clinical interpretation of germline TP53 variants
Autor: | Raad, Sabine, Rolain, Marion, Coutant, Sophie, Derambure, Céline, Lanos, Raphael, Charbonnier, Françoise, Bou, Jacqueline, Bouvignies, Emilie, Lienard, Gwendoline, Vasseur, Stéphanie, Farrell, Michael, Ingster, Olivier, Baert Desurmont, Stéphanie, Kasper, Edwige, Bougeard, Gaëlle, Frébourg, Thierry, Tournier, Isabelle |
---|---|
Přispěvatelé: | Génomique et Médecine Personnalisée du Cancer et des Maladies Neuropsychiatriques (GPMCND), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM) |
Jazyk: | angličtina |
Rok vydání: | 2020 |
Předmět: |
Adult
Male Adolescent Genotype DNA Mutational Analysis clinical laboratory techniques Reproducibility of Results Middle Aged Polymorphism Single Nucleotide genetic testing methods Young Adult [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics Child Preschool Neoplasms Leukocytes Mononuclear Cancer Genetics Humans Female Genetic Predisposition to Disease Tumor Suppressor Protein p53 Child Germ-Line Mutation Aged |
Zdroj: | Journal of Medical Genetics Journal of Medical Genetics, BMJ Publishing Group, 2020, pp.jmedgenet-2020-107059. ⟨10.1136/jmedgenet-2020-107059⟩ |
ISSN: | 1468-6244 0022-2593 |
Popis: | Background The interpretation of germline TP53 variants is critical to ensure appropriate medical management of patients with cancer and follow-up of variant carriers. This interpretation remains complex and is becoming a growing challenge considering the exponential increase in TP53 tests. We developed a functional assay directly performed on patients’ blood. Methods Peripheral blood mononuclear cells were cultured, activated, exposed to doxorubicin and the p53-mediated transcriptional response was quantified using reverse transcription–multiplex ligation probe amplification and RT-QMPSF assays, including 10 p53 targets selected from transcriptome analysis, and two amplicons to measure p53 mRNA levels. We applied this blood functional assay to 77 patients addressed for TP53 analysis. Results In 51 wild-type TP53 individuals, the mean p53 functionality score was 12.7 (range 7.5–22.8). Among eight individuals harbouring likely pathogenic or pathogenic variants, the scores were reduced (mean 4.8, range 3.1–7.1), and p53 mRNA levels were reduced in patients harbouring truncating variants. We tested 14 rare unclassified variants (p.(Pro72His), p.(Gly105Asp), p.(Arg110His), p.(Phe134Leu), p.(Arg158Cys), p.(Pro191Arg), p.(Pro278Arg), p.(Arg283Cys), p.(Leu348Ser), p.(Asp352Tyr), p.(Gly108_Phe109delinsVal), p.(Asn131del), p.(Leu265del), c.-117G>T) and 12 yielded functionally abnormal scores. Remarkably, the assay revealed that the c.*1175A>C polymorphic variant within TP53 poly-adenylation site can impact p53 function with the same magnitude as a null variant, when present on both alleles, and may act as a modifying factor in pathogenic variant carriers. Conclusion This blood p53 assay should therefore be a useful tool for the rapid clinical classification of germline TP53 variants and detection of non-coding functional variants. |
Databáze: | OpenAIRE |
Externí odkaz: |